Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:26:06.123Z.
Calculation as of: 2026-10-06T18:26:06.123Z.
Quote observation: 2026-10-06T18:24:35.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ea268c636d02c1563f9a0cc17fa45ef3048b6802d4031696aa30e1bc9d7aaf2a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Connect Biopharma Holdings Limited
Market Cap
$59.03M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$57.88M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$60.89M
Price/FCF Ratio
N/A
TTM Avg
2.61
3Y Avg
2.61
5Y Avg
2.61
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Connect Biopharma Holdings Limited (CNTB) | $59.03M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.78M | N/A | 98.33 | 98.33 | 98.33 |
| PDS Biotechnology Corporation (PDSB)vs › | $57.88M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.98M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.54M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $60.68M | N/A | N/A | N/A | N/A |
| Talphera, Inc. (TLPH)vs › | $57.09M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.89M | N/A | 2.61 | 2.61 | 2.61 |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
